home > drugs a-z list > multihance (gadobenate dimeglumine injection) drug center > multihance (gadobenate dimeglumine injection) drug - overdosage and contraindications

Clinical consequences of over dosage with MultiHance (gadobenate dimeglumine injection) have not been reported. Treatment of an over- dosage should be directed toward support of vital functions and prompt institution of symptomatic therapy. In a Phase 1 clinical study, doses up to 0.4 mmol/kg were administered to patients. MultiHance has been shown to be dialyzable [see CLINICAL PHARMACOLOGY].

MultiHance (gadobenate dimeglumine injection) is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium-based contrast agents [see WARNINGS AND PRECAUTIONS].

Last reviewed on RxList: 2/10/2011
This monograph has been modified to include the generic and brand name in many instances.